MD, PhD| Nephrologist| Hereditary Kidney Disease Fellow-UHN| IMS UofTo| ADPKD| AI in Med| @GlomCon educator| @GlomConILA| 🇨🇴🇪🇸🇨🇦🌐
Joined April 2019
- Tweets 1,437
- Following 1,010
- Followers 1,649
- Likes 1,671
366 Photos and videos
Today we had an outstanding talk about clinical trials in ADPKD by Dr. @fouadchebib from Mayo Clinic Florida at @GlomCon PKD-MDP.
-Consideration for Tolvaptan initiation and referral for possible clinical trials.
-Key Milestones in ADPKD and clinical trials
4
13
994
Sol Carriazo, Neph. retweeted
Jun 4
Another win for IgAN thelancet.com/journals/lance… @TheLancet Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
7
18
850
Obinutuzumab vs Tacrolimus in Primary Membranous Nephropathy
Presented at #ERA26:
In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: nej.md/4dZsVPD
@ERAkidney
ALT A line graph from an article published in the New England Journal of Medicine compares obinutuzumab and tacrolimus in treating primary membranous nephropathy over 104 weeks. The y-axis represents the percentage of patients relapse‑free, while the x-axis represents weeks. The graph shows two lines, one for obinutuzumab and another for tacrolimus. The image mentions the European Renal Association Congress at the top.
2
10
699
Finerenone in adults with CKD without diabetes
Presented at #ERA26:
In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months. Full phase 3 FIND-CKD trial results: nej.md/4wWOFV4
@ERAkidney
ALT Graph comparing mean eGFR slopes between finerenone and placebo groups. The chart has three sections: Total, Baseline to Month 3, and Month 3 to End of Treatment. Numerical values are provided above the bars, showing treatment differences with confidence intervals.
1
3
22
5,191
Sol Carriazo, Neph. retweeted
🚨No te pierdas este sábado el seminario:
☞ El rol de la microscopía electrónica en el diagnóstico de las glomerulopatías 🔬
🗓️ 6/junio/26
🗣️ Dra. Fernanda Toniolo 🇦🇷
🕘 9 am CDMX
Zoom ID: 863 6358 3637
Pass: 343 190
#GlomConAmor #GlomConILA
9
15
911
Sol Carriazo, Neph. retweeted
🧬#ADPKD is far more than a #KidneyDisease🧬
It may represent a #systemicvasculopathy driven by #polycystin dysfunction and impaired vascular integrity.
🤔Implications: higher suspicion for acute chest/abdominal pain
ajkd.org/article/S0272-6386%…
3
16
700
Sol Carriazo, Neph. retweeted
🚨No te pierdas este sábado el seminario:
☞ Síndrome Riñón-Pulmón
🗣️ Dra. Diana Carolina Vargas 🇨🇴
🗓️23/Mayo/26
🕘9 am CDMX
Zoom ID: 863 6358 3637
Pass: 343 190
#GlomConAmor #GlomConILA
6
14
827
Measuring the Impact of tolvaptan-induced polyuria on quality of life in patients with autosomal dominant polycystic kidney disease
Now open access in @NDTsocial
Tolvaptan-induced polyuria and QoL in pts with ADPKD
🧐 This new questionnaire captures the physical, mental, and social burden of tolvaptan-induced polyuria, and provides a reliable PROM for clinical care and research
▶️academic.oup.com/ndt/article…
1
5
565
Sol Carriazo, Neph. retweeted
🚨No te pierdas este sábado el seminario:
☞ Lo nuevo de LRA en KDIGO: volumen, fluidos y HRS-AKI
🗓️ 9/Mayo/26
🗣️ Dr. Hector Antonio Navarrete 🇲🇽
🕘 9 am CDMX
Zoom ID: 863 6358 3637
Pass: 343 190
#GlomConAmor #GlomConILA
1
4
9
863
Sol Carriazo, Neph. retweeted
Now open access in @NDTsocial
KDIGO 2025 ADPKD Guideline: a commentary on intracranial aneurysms and other vascular manifestations from the ERA Working Group Genes & Kidney
▶️academic.oup.com/ndt/article…
7
13
945
Sol Carriazo, Neph. retweeted
Our amazing Sol giving a talk on ADPKD based on her @TheLancet paper today at @GlomCon PKD fellowship
thelancet.com/journals/lance…
1
9
27
3,130
Sol Carriazo, Neph. retweeted
Today at #PKDMDP @GlomCon we learned more about Polycystic Kidney Disease from Dr. Sol Carriazo @Nefrontera by reviewing her recent paper published in The Lancet @TheLancet
doi.org/10.1016/S0140-6736(2…
2
3
17
744
Sol Carriazo, Neph. retweeted
Renal cysts does NOT automatically equal ADPKD. So what is NOT ADPKD? Check out this slide by @Nefrontera from her lecture "ADPKD: An Updated Review."
@GlomCon PKD-MD Program
14
28
1,453
Thank you so much for the invitation! @kidneymo @SaynaNorouzi ❤️
Thrilled to have @Nefrontera as our speaker today in the @GlomCon PKD-MD Program presenting an updated review on ADPKD based on her recently published review article in @TheLancet
Link to article: thelancet.com/article/S0140-…
1
4
321
¡Muchas gracias por la invitación! Ha sido un honor poder compartir este espacio y conversar sobre un tema tan importante para la región. 💙🧬
Apr 10
Cada vez el nefrólogo se debe de familiarizar más con la genética y conocer nuestra historia como Latinos🧬
La Dra @Nefrontera nos da un gran repaso en las genética de las enfermedades renales crónicas de causa desconocida en Latinoamérica.
@IMINmx
#Nefrología #ERC #Genética #EducaciónMédica #Nefropatología #Glomerulares #Podocitopatías
1
240
Sol Carriazo, Neph. retweeted
🚨No te pierdas este sábado el seminario:
☞ Glomerulopatías silenciosas: el poder diagnóstico de la atención primaria 👩🏻⚕️👨🏻⚕️
🗓️ 28/Marzo/26
🗣️ Dr. Enzo Vera
🕘 9 am CDMX
Zoom ID: 863 6358 3637
Pass: 343 190
#GlomConAmor #GlomConILA
6
14
2,020
Sol Carriazo, Neph. retweeted
It was wonderful working with this amazing group of PKD experts to provide the US perspective on the global @goKDIGO ADPKD guidelines.
Check out this figure for chapter 4
@PKDFoundation @PkdResearch @MayoClinicNeph
Mar 21
#KDOQI US Commentary on @goKDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of #ADPKD
bit.ly/KDOQIADPKD26 (FREE)
@ndahl48 @PauAugust @fouadchebib @michelchonchol @mariehogan_md @RonakLakhia1 @KristenlNowak @AlanYuNeph @terry_watnickmd
26
73
5,796
Sol Carriazo, Neph. retweeted
How can genomics and Mendelian randomization help drug targets traverse the "Valley of Death" in kidney research?
Please see and share our new paper:
kireports.org/article/S2468-…
1
4
426
Sol Carriazo, Neph. retweeted
Good morning, everyone! 😊 Kicking off the day moderating an incredible session by Dr. Hartung on PKD management in pediatrics and transition care at #PKDMDP @GlomCon #Nephrology #KidneyHealth #RareKidneyDiseases
@Nefrontera @kidneymo
@fouadchebib @pranavgarimella Dr. Dahl
8
19
1,550
Honored to share our Review published in @TheLancet about ADPKD
Highlighting advances in genetics, imaging, and disease-modifying therapies.
Grateful to collaborate with such an exceptional team led by Dr. Y. Pei from @UHN, Dr. R. Torra, Dr. A. Ong and Dr. B. Mingyao
👇🏽
7
43
140
7,044